Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects

BACKGROUND: Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies. METHODS: We performed a drug screen for tumor cell PDL1 depleti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Haiyan, Padron, Alvaro S, Deng, Yilun, Liao, Yiji J, Murray, Clare J, Ontiveros, Carlos, Kari, Suresh J, Kancharla, Aravind, Kornepati, Anand V R, Garcia, Myrna, Reyes, Ryan Michael, Gupta, Harshita B, Conejo-Garcia, Jose R, Curiel, Tyler
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923271/
https://www.ncbi.nlm.nih.gov/pubmed/36759012
http://dx.doi.org/10.1136/jitc-2022-004871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923271/
https://www.ncbi.nlm.nih.gov/pubmed/36759012
http://dx.doi.org/10.1136/jitc-2022-004871

Ejemplares similares